View more in
Cancer

Dr. Raghav on Selecting Treatment with TAS-102 vs Regorafenib in CRC

onclive.com
 2021-05-10

Kanwal Raghav, MBBS, MD, discusses the process for selecting between treatment with trifluridine and tipiracil vs regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the process for selecting between treatment with trifluridine and tipiracil (Lonsurf; TAS-102) vs regorafenib (Stivarga) in patients with colorectal cancer (CRC).

www.onclive.com

Comments / 0

Comments / 0